Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$32.23
0.672.12%
À la fermeture: -
$32.23
0.000.00%
Après les heures de négociation: 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Imax Corp a un objectif de cours consensus de $31, basé sur les évaluations des 14 analystes. Le plus élevé est de $42 attribué par Rosenblatt le octobre 9, 2025, et le plus bas est de $13 attribué par Goldman Sachs le janvier 11, 2024. Les 3 dernières évaluations d'analystes ont été publiées par Roth Capital, Rosenblatt et JP Morgan le octobre 14, 2025, octobre 9, 2025 et octobre 9, 2025. Avec un objectif de cours moyen de $37.67 entre Roth Capital, Rosenblatt et JP Morgan, il y a une variation implicite de 16.87% upside pour Imax Corp à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Roth Capital
Rosenblatt
JP Morgan
Barrington Research
Wedbush
1calculé à partir des notes des analystes
Notes d'analystes pour Imax
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/14/2025 | 24.11% | Roth Capital | $36 → $40 | Maintains | Buy | |||
10/09/2025 | 30.31% | Rosenblatt | $37 → $42 | Maintains | Buy | |||
10/09/2025 | -3.82% | JP Morgan | $28 → $31 | Maintains | Neutral | |||
09/23/2025 | 14.8% | Barrington Research | $37 → $37 | Maintains | Outperform | |||
09/22/2025 | 21.01% | Wedbush | $35 → $39 | Maintains | Outperform | |||
09/19/2025 | 14.8% | Barrington Research | $32 → $37 | Maintains | Outperform | |||
07/25/2025 | 5.49% | Wells Fargo | $30 → $34 | Maintains | Overweight | |||
07/25/2025 | 8.59% | Wedbush | $34 → $35 | Maintains | Outperform | |||
07/25/2025 | -0.71% | Benchmark | $30 → $32 | Maintains | Buy | |||
07/25/2025 | 14.8% | Rosenblatt | $35 → $37 | Maintains | Buy | |||
07/24/2025 | -0.71% | Barrington Research | $32 → $32 | Maintains | Outperform | |||
07/11/2025 | 8.59% | Rosenblatt | $35 → $35 | Maintains | Buy | |||
07/09/2025 | 11.7% | Roth Capital | $36 → $36 | Reiterates | Buy → Buy | |||
06/16/2025 | 8.59% | Rosenblatt | $35 → $35 | Maintains | Buy | |||
06/13/2025 | 11.7% | Roth Capital | $32 → $36 | Maintains | Buy | |||
04/25/2025 | -0.71% | Macquarie | $30 → $32 | Maintains | Outperform | |||
04/24/2025 | -0.71% | Barrington Research | $32 → $32 | Maintains | Outperform | |||
04/24/2025 | -6.92% | Wells Fargo | $32 → $30 | Maintains | Overweight | |||
04/24/2025 | 8.59% | Rosenblatt | $35 → $35 | Maintains | Buy | |||
04/11/2025 | -19.33% | JP Morgan | $27 → $26 | Maintains | Neutral | |||
04/10/2025 | -6.92% | Benchmark | $30 → $30 | Reiterates | Buy → Buy | |||
04/10/2025 | 8.59% | Rosenblatt | $35 → $35 | Maintains | Buy | |||
02/21/2025 | -16.23% | JP Morgan | $25 → $27 | Maintains | Neutral | |||
02/20/2025 | -6.92% | Macquarie | $28 → $30 | Maintains | Outperform | |||
02/20/2025 | -0.71% | Barrington Research | $30 → $32 | Maintains | Outperform | |||
02/20/2025 | -6.92% | Benchmark | $30 → $30 | Reiterates | Buy → Buy | |||
02/20/2025 | -0.71% | Wells Fargo | $26 → $32 | Maintains | Overweight | |||
02/20/2025 | 8.59% | Rosenblatt | $28 → $35 | Maintains | Buy | |||
02/12/2025 | -0.71% | Wedbush | $32 → $32 | Reiterates | Outperform → Outperform | |||
01/30/2025 | -22.43% | JP Morgan | $21 → $25 | Maintains | Neutral | |||
01/17/2025 | -6.92% | Benchmark | $30 → $30 | Reiterates | Buy → Buy | |||
01/16/2025 | -13.12% | Rosenblatt | $28 → $28 | Maintains | Buy | |||
01/13/2025 | -6.92% | Benchmark | $30 → $30 | Reiterates | Buy → Buy | |||
01/10/2025 | -6.92% | Barrington Research | $30 → $30 | Maintains | Outperform | |||
01/10/2025 | -6.92% | Benchmark | $30 → $30 | Reiterates | Buy → Buy | |||
12/13/2024 | -6.92% | Benchmark | $27 → $30 | Maintains | Buy | |||
11/27/2024 | -0.71% | Wedbush | $26 → $32 | Maintains | Outperform | |||
11/01/2024 | -16.23% | Macquarie | $26 → $27 | Maintains | Outperform | |||
11/01/2024 | -13.12% | Barrington Research | $24 → $28 | Maintains | Outperform | |||
10/31/2024 | -13.12% | Roth MKM | $27 → $28 | Maintains | Buy | |||
10/31/2024 | -25.54% | Barrington Research | $24 → $24 | Maintains | Outperform | |||
10/31/2024 | -13.12% | Rosenblatt | $28 → $28 | Maintains | Buy | |||
10/14/2024 | -34.84% | JP Morgan | $20 → $21 | Maintains | Neutral | |||
10/10/2024 | -16.23% | Roth MKM | $27 → $27 | Maintains | Buy | |||
10/04/2024 | -13.12% | Rosenblatt | $28 → $28 | Maintains | Buy | |||
09/25/2024 | -25.54% | Barrington Research | $24 → $24 | Maintains | Outperform | |||
09/03/2024 | -19.33% | Wedbush | $24 → $26 | Maintains | Outperform | |||
07/26/2024 | -16.23% | Roth MKM | $23 → $27 | Maintains | Buy | |||
07/26/2024 | -13.12% | Rosenblatt | $25 → $28 | Maintains | Buy | |||
07/26/2024 | -25.54% | Wedbush | $22 → $24 | Maintains | Outperform | |||
07/26/2024 | -22.43% | Barrington Research | $25 → $25 | Maintains | Outperform | |||
07/26/2024 | -19.33% | Macquarie | $24 → $26 | Maintains | Outperform | |||
07/24/2024 | -28.64% | Seaport Global | → $23 | Initiates | → Buy | |||
07/18/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
07/18/2024 | -28.64% | Roth MKM | $22 → $23 | Maintains | Buy | |||
07/08/2024 | -6.92% | B. Riley Securities | $27 → $30 | Maintains | Buy | |||
06/20/2024 | -31.74% | Benchmark | $22 → $22 | Reiterates | Buy → Buy | |||
06/17/2024 | -22.43% | Rosenblatt | $25 → $25 | Maintains | Buy | |||
04/26/2024 | -31.74% | Benchmark | $22 → $22 | Reiterates | Buy → Buy | |||
04/26/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
04/25/2024 | -25.54% | Barrington Research | $24 → $24 | Maintains | Outperform | |||
04/22/2024 | -25.54% | Barrington Research | $24 → $24 | Maintains | Outperform | |||
04/18/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
04/16/2024 | -31.74% | Benchmark | $22 → $22 | Reiterates | Buy → Buy | |||
04/10/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
04/10/2024 | -31.74% | Benchmark | $22 → $22 | Reiterates | Buy → Buy | |||
03/04/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
03/04/2024 | -25.54% | Barrington Research | → $24 | Reiterates | Outperform → Outperform | |||
02/28/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
02/28/2024 | -25.54% | Barrington Research | → $24 | Reiterates | Outperform → Outperform | |||
02/23/2024 | -31.74% | Wedbush | $22 → $22 | Reiterates | Outperform → Outperform | |||
02/13/2024 | -22.43% | Rosenblatt | $30 → $25 | Maintains | Buy | |||
02/06/2024 | -47.25% | JP Morgan | $20 → $17 | Maintains | Neutral | |||
01/18/2024 | -31.74% | Benchmark | $24 → $22 | Maintains | Buy | |||
01/11/2024 | -59.66% | Goldman Sachs | $15 → $13 | Maintains | Sell | |||
01/02/2024 | -34.84% | B. Riley Securities | $27 → $21 | Maintains | Buy | |||
12/05/2023 | -6.92% | Rosenblatt | → $30 | Reiterates | Buy → Buy | |||
10/10/2023 | -6.92% | Rosenblatt | → $30 | Reiterates | Buy → Buy | |||
10/09/2023 | -25.54% | Benchmark | $23 → $24 | Maintains | Buy | |||
08/25/2023 | -6.92% | Rosenblatt | $27 → $30 | Maintains | Buy | |||
08/18/2023 | -6.92% | Rosenblatt | $27 → $30 | Maintains | Buy | |||
07/28/2023 | -25.54% | Barrington Research | → $24 | Reiterates | Outperform → Outperform | |||
07/27/2023 | -19.33% | Wedbush | → $26 | Reiterates | Outperform → Outperform | |||
07/27/2023 | -6.92% | Rosenblatt | $27 → $30 | Maintains | Buy | |||
07/20/2023 | -19.33% | Wedbush | → $26 | Reiterates | Outperform → Outperform | |||
07/13/2023 | -28.64% | Benchmark | → $23 | Reiterates | Buy → Buy | |||
07/13/2023 | -19.33% | Wedbush | → $26 | Reiterates | Outperform → Outperform | |||
07/13/2023 | -16.23% | Rosenblatt | → $27 | Reiterates | Buy → Buy | |||
07/12/2023 | -19.33% | Roth MKM | $26 → $26 | Reiterates | Buy → Buy | |||
05/02/2023 | -25.54% | Barrington Research | → $24 | Reiterates | → Outperform | |||
05/02/2023 | -28.64% | Benchmark | $22 → $23 | Maintains | Buy | |||
04/28/2023 | -16.23% | B. Riley Securities | $26 → $27 | Maintains | Buy | |||
04/28/2023 | -19.33% | Roth MKM | $24 → $26 | Maintains | Buy | |||
04/28/2023 | -22.43% | Wells Fargo | $22 → $25 | Maintains | Overweight | |||
04/28/2023 | -16.23% | Rosenblatt | $25 → $27 | Maintains | Buy | |||
04/25/2023 | -22.43% | Wedbush | $22 → $25 | Maintains | Outperform | |||
04/10/2023 | -19.33% | B. Riley Securities | $23 → $26 | Maintains | Buy | |||
04/05/2023 | -22.43% | Rosenblatt | → $25 | Reiterates | → Buy | |||
02/28/2023 | -56.56% | Goldman Sachs | $12 → $14 | Maintains | Sell | |||
02/23/2023 | -37.95% | Barrington Research | → $20 | Reiterates | → Outperform |
FAQ
Quel est le cours indicatif de l'action Imax (IMAX) ?
Le dernier objectif de prix pour Imax (NYSE:IMAX) a été rapporté par Roth Capital le octobre 14, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $40.00 s'attendant à ce que IMAX se rise dans les 12 prochains mois (un possible changement de 24.11% upside). 42 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Imax (IMAX) ?
La dernière note d'analyste pour Imax (NYSE:IMAX) a été fournie par Roth Capital, et Imax maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Imax (IMAX) ?
Il n'y a pas de dernière amélioration pour Imax
Quand a eu lieu la dernière dégradation pour Imax (IMAX) ?
Il n'y a pas de dernière réduction pour Imax.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Imax (IMAX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Imax, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Imax a été déposée le octobre 14, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 14, 2026.
La note d'analyste pour Imax (IMAX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Imax (IMAX) était un maintenu avec un objectif de prix de $36.00 à $40.00. Le prix actuel de Imax (IMAX) est de $32.23, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.